Subscribe To
Cap-weighting crucial when indexing biotech
The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams beca...
January 25, 2022, 1:53 pm
Why checkpoint therapeutics stock is heating up today
Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment fo...
January 25, 2022, 10:06 am
Why checkpoint therapeutics stock is heating up today
Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment fo...
January 25, 2022, 10:06 am
Why checkpoint therapeutics stock is heating up today
Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment fo...
January 25, 2022, 10:06 am
5 psychedelic therapeutics decisions coming in 2022
biotech and pharmaceutical companies are generally involved in the lengthy process of getting their dru...
January 25, 2022, 7:35 am
5 psychedelic therapeutics decisions coming in 2022
biotech and pharmaceutical companies are generally involved in the lengthy process of getting their dru...
January 25, 2022, 7:35 am
5 psychedelic therapeutics decisions coming in 2022
biotech and pharmaceutical companies are generally involved in the lengthy process of getting their dru...
January 25, 2022, 7:35 am
Cassava sciences is an exciting roll-the-dice biotech trade
Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. The post ...
January 24, 2022, 3:02 pm
Cassava sciences is an exciting roll-the-dice biotech trade
Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. The post ...
January 24, 2022, 3:02 pm
Cassava sciences is an exciting roll-the-dice biotech trade
Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. The post ...
January 24, 2022, 3:02 pm
Pfizer, astrazeneca or j&j covid-19 shots boost sinovac regime, brazilian study shows
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or J...
January 24, 2022, 12:44 pm
Pfizer, astrazeneca or j&j covid-19 shots boost sinovac regime, brazilian study shows
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or J...
January 24, 2022, 12:44 pm
Pfizer, astrazeneca or j&j covid-19 shots boost sinovac regime, brazilian study shows
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or J...
January 24, 2022, 12:44 pm
3 unstoppable biotech stocks to buy right now
All of them have tremendous growth prospects....
January 24, 2022, 6:04 am
3 unstoppable biotech stocks to buy right now
All of them have tremendous growth prospects....
January 24, 2022, 6:04 am
3 unstoppable biotech stocks to buy right now
All of them have tremendous growth prospects....
January 24, 2022, 6:04 am
Alnylam: biotech to watch with potential fda approval of vutrisiran for rare disease
Alnylam reported positive 18-month results using its drug vutrisiran for the treatment of patients with ATTR with polyneuropathy. A PDUFA date is set ...
January 22, 2022, 11:17 am
Alnylam: biotech to watch with potential fda approval of vutrisiran for rare disease
Alnylam reported positive 18-month results using its drug vutrisiran for the treatment of patients with ATTR with polyneuropathy. A PDUFA date is set ...
January 22, 2022, 11:17 am
Alnylam: biotech to watch with potential fda approval of vutrisiran for rare disease
Alnylam reported positive 18-month results using its drug vutrisiran for the treatment of patients with ATTR with polyneuropathy. A PDUFA date is set ...
January 22, 2022, 11:17 am
Jim cramer considers the investment cases for nautilus biotechnology and cyxtera technologies
On Friday's episode of "Mad Money," host Jim Cramer reviewed the investment cases for Nautilus Biotechnology and Cyxtera Technologies, two companies t...
January 21, 2022, 8:11 pm